Ann: Appendix 4C - Quarterly, page-25

And whilst the whiners sell down on slow past progress communication we've all witnessed and some have addressed with company (hence less so recently I'd argue), the FDA grants yet another IND to a stem cell therapy:

https://www.prnewswire.com/news-releases/vitti-labs-announces-fda-approval-of-phase-ii-ind-clinical-trial-of-combination-mesenchymal-stem-cell-and-exosome-treatment-of-pulmonary-fibrosis-secondary-to-novel-corona-virus-infection-covid-19-301536686.html

A nice regulatory backdrop for a company looking at "accelerating its US commercialisation plans with technology scale up, FDA engagement and commercial preparation activities being advanced to support a Phase 2b randomised controlled study for FDA submission." as communicated in this Appendix 4C.

IND's have been granted in increasing numbers by the FDA with regard to stem cell therapies (you might recall BioCardia I flagged three weeks ago).